Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Journal:
Current Pharmaceutical Design
Volume:
26
Page:
3234-3250
Author(s):
Sushil K. Kashaw*, Prashant Sahu, Vaibhav Rajoriya, Pradeep Jana, Varsha Kashaw, Samaresh Sau and Arun K. Iyer*
Roles of Medicinal Plants and Constituents in Gynecological Cancer Therapy: Current Literature and Future Directions
Journal:
Current Topics in Medicinal Chemistry
Volume:
20
Page:
1772-1790
Author(s):
Esra Küpeli Akkol*, Fatma Tuğçe Gürağaç Dereli, Eduardo Sobarzo-Sánchez and Haroon Khan
Kinase Phosphorylation-based Mechanisms of PARP Inhibitor Resistance During Synthetic Lethal Oncotherapy
Journal:
Current Signal Transduction Therapy
Volume:
15
Page:
12-23
Author(s):
Eriko Osaki and Shinya Mizuno*
ACE2/Angiotensin-(1-7)/Mas Receptor Axis in Human Cancer: Potential Role for Pediatric Tumors
Journal:
Current Drug Targets
Volume:
21
Page:
892-901
Author(s):
Ana Luiza Ataide Carneiro de Paula Gonzaga , Vitória Andrade Palmeira , Thomas Felipe Silva Ribeiro , Larissa Braga Costa , Karla Emília de Sá Rodrigues and Ana Cristina Simões-e-Silva *
Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?
Journal:
Current Drug Targets
Volume:
21
Page:
1026-1033
Author(s):
Khalid El Bairi*, Said Afqir and Mariam Amrani
Curcumin Sensitizes Cancers Towards TRAIL-induced Apoptosis via Extrinsic and Intrinsic Apoptotic Pathways
Journal:
Current Drug Targets
Volume:
21
Page:
849-854
Author(s):
Siew Ching Ngai*
BRCA Mutational Status is a Promising Predictive Biomarker for Platinum- based Chemotherapy in Triple-Negative Breast Cancer
Journal:
Current Drug Targets
Volume:
21
Page:
962-973
Author(s):
Amal Tazzite*, Hassan Jouhadi, Abdellatif Benider and Sellama Nadifi
The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Journal:
Current Drug Targets
Volume:
21
Page:
946-961
Author(s):
Csongor György Lengyel*, Sara Cecilia Altuna, Baker Shalal Habeeb, Dario Trapani and Shah Zeb Khan
Exploring the Clinical Impact of Predictive Biomarkers in Serous Ovarian Carcinomas
Journal:
Current Drug Targets
Volume:
21
Page:
974-995
Author(s):
Cécile Le Page*, Jacqueline Chung, Kurosh Rahimi, Martin Köbel, Diane Provencher and Anne-Marie Mes-Masson
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Journal:
Current Drug Targets
Volume:
21
Page:
996-1007
Author(s):
Soumaya Souid*, Dorra Aissaoui, Najet Srairi-Abid and Khadija Essafi-Benkhadir